Versor Investments LP Makes New Investment in agilon health, inc. (NYSE:AGL)

Posted by Defense World Staff on Apr 15th, 2023

Versor Investments LP bought a new stake in shares of agilon health, inc. (NYSE:AGL – Get Rating) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 24,700 shares of the company’s stock, valued at approximately $399,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Synovus Financial Corp boosted its stake in shares of agilon health by 5.1% during the 3rd quarter. Synovus Financial Corp now owns 10,671 shares of the company’s stock valued at $251,000 after buying an additional 518 shares during the last quarter. Trexquant Investment LP boosted its stake in shares of agilon health by 1.2% during the 3rd quarter. Trexquant Investment LP now owns 53,913 shares of the company’s stock valued at $1,263,000 after buying an additional 657 shares during the last quarter. Xponance Inc. boosted its stake in shares of agilon health by 3.8% during the 3rd quarter. Xponance Inc. now owns 21,509 shares of the company’s stock valued at $504,000 after buying an additional 778 shares during the last quarter. IFP Advisors Inc boosted its stake in shares of agilon health by 236.3% during the 3rd quarter. IFP Advisors Inc now owns 1,231 shares of the company’s stock valued at $38,000 after buying an additional 865 shares during the last quarter. Finally, Victory Capital Management Inc. boosted its stake in shares of agilon health by 4.1% during the 3rd quarter. Victory Capital Management Inc. now owns 23,797 shares of the company’s stock valued at $557,000 after buying an additional 942 shares during the last quarter.

Insiders Place Their Bets

In other agilon health news, insider Benjamin Shaker sold 20,723 shares of the stock in a transaction on Wednesday, January 18th. The stock was sold at an average price of $19.78, for a total value of $409,900.94. Following the sale, the insider now directly owns 25,625 shares of the company’s stock, valued at $506,862.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other agilon health news, insider Benjamin Kornitzer sold 8,094 shares of the stock in a transaction on Wednesday, March 8th. The stock was sold at an average price of $24.44, for a total value of $197,817.36. Following the sale, the insider now directly owns 10,426 shares of the company’s stock, valued at $254,811.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Benjamin Shaker sold 20,723 shares of the stock in a transaction on Wednesday, January 18th. The stock was sold at an average price of $19.78, for a total value of $409,900.94. Following the completion of the sale, the insider now directly owns 25,625 shares in the company, valued at $506,862.50. The disclosure for this sale can be found here. Insiders have sold 70,862 shares of company stock valued at $1,609,493 over the last three months. Company insiders own 3.30% of the company’s stock.

agilon health Price Performance

Shares of NYSE AGL opened at $28.46 on Friday. agilon health, inc. has a 1-year low of $14.82 and a 1-year high of $29.44. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.71 and a quick ratio of 2.71. The business’s fifty day moving average price is $24.61 and its two-hundred day moving average price is $20.99. The firm has a market capitalization of $11.76 billion, a PE ratio of -109.46 and a beta of 1.13.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the company. Guggenheim increased their target price on agilon health from $21.00 to $30.00 and gave the company a “buy” rating in a research note on Monday, March 6th. Wells Fargo & Company upped their price target on agilon health from $22.00 to $28.00 in a research report on Thursday, March 16th. Finally, Deutsche Bank Aktiengesellschaft upped their price target on agilon health from $26.00 to $28.00 in a research report on Friday, March 3rd. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $29.38.

agilon health Profile

(Get Rating)

agilon health, inc. offers healthcare services for seniors through primary care physicians in the communities of the United States. As of December 31, 2021, it served approximately 238,000 senior members, which included 186,300 medicare advantage members and 51,700 medicare fee-for-service beneficiaries.